What is the T(pot) for prostate cancer? Radiobiological implications of the equivalent outcome with 125I or 103Pd

International Journal of Radiation Oncology Biology Physics

Volumn 47, Issue 5, 2000, Pages 1165-1167

  King, C R ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125; ISOTOPE; PALLADIUM; PALLADIUM 103; UNCLASSIFIED DRUG;

BRACHYTHERAPY; CANCER CELL CULTURE; CELL SURVIVAL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; RADIOBIOLOGY; RELATIVE BIOLOGIC EFFECTIVENESS; SHORT SURVEY; TIME;

EID: 0034662315     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00543-5     Document Type: Letter

References (18)

1. C.M Cha L Potters R Ashley Isotope selection for patients undergoing prostate brachytherapy Int J Radiat Oncol Biol Phys 45 1999 391 395
2. C.C Ling Permanent implants using Au-198, Pd-103 and I-125 Radiobiologic considerations based on the linear quadratic model Int J Radiat Oncol Biol Phys 23 1992 81 87
3. C.C Ling W.X Li L.L Anderson The relative biologic effectiveness of I-125 and Pd-103 Int J Radiat Oncol Biol Phys 32 1995 373 378
4. O Algan C.C Stobbe A.M Helt Radiation inactivation of human prostate cancer cells The role of apoptosis Radiat Res 146 1996 267 275
5. J.T Leith L Quaranto G Padfield Radiobiological studies of PC-3 and DU-145 human prostate cancer cells X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo Int J Radiat Oncol Biol Phys 25 1993 283 287
6. T.L DeWeese J.M Shipman L.E Dillehay Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure J Urol 159 1998 591 598
7. D.J Brenner E.J Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101
8. G.M Duschesne L.J Peters What is the α/β ratio for prostate cancer? rationale for hypofractionated high-dose-rate brachytherapy Int J Radiat Oncol Biol Phys 44 1999 747 748
9. C.R King C.S Mayo Is the α/β ratio of 1.5 from Brenner and Hall a modeling artifact? Int J Radiat Oncol Biol Phys 47 2000 536 538
10. K.M.G Haustermans I Hofland H Van Poppel Cell kinetic measurements in prostate cancer Int J Radiat Oncol Biol Phys 37 1997 1067 1070
11. W.R Lee G.E Hanks B.W Corn Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy Int J Radiat Oncol Biol Phys 31 1995 21 24
12. H.P Schmid Tumour markers in patients on deferred treatment Prostate specific antigen doubling times Cancer Surv 23 1995 157 167
13. B Movsas J.D Chapman E.M Horwitz Hypoxic regions exist in human prostate carcinoma Urology 53 1999 11 18
14. J.S Rasey W.-J Koh M.L Evans Quantifying regional hypoxia in human tumors with positron emission tomography of fluoromisonidazole A pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
15. R.G Dale The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br J Radiol 58 1985 515 528
16. R.G Dale Radiobiological assessment of permanent implants using tumor repopulation factors in the linear-quadratic model Br J Radiol 62 1989 241 244
17. C.C Ling J Roy N Sahoo Quantifying the effect of dose inhomogeneity in brachytherapy Application to permanent prostatic implant with I-125 seeds Int J Radiat Oncol Biol Phys 28 1994 971 978
18. C.R King T.A DiPetrillo D.E Wazer Optimal radiotherapy for prostate cancer predictions for conventional external beam, IMRT and brachytherapy from radiobiologic models Int J Radiat Oncol Biol Phys 46 2000 165 172